Press Releases | Alexion Pharmaceuticals, Inc

About Alexion
Patient Focus
Products
Research & Development
Responsibility
Careers
Select a Country
- North America
  - Canada
  - USA
- Latin America
  - Argentina
  - Brazil
  - Colombia
  - Mexico
- Europe, the Middle East & Africa
  - Alexion Europe
  - Belgium
  - Denmark
  - France
  - Germany
  - Ireland
  - Italy
  - Netherlands
  - Norway
  - Russia
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - UAE
  - UK
- Asia Pacific
  - Australia
  - China
  - India
  - Japan
Investors
News
Contact

Home
»
Newsroom
»
Press Releases

Press Releases

All News Releases

Alexion Adds Paul A. Friedman, M.D. to Its Board of Directors
September 14, 2017
HTML PDF
Interim Analysis from Phase 3 Open-Label Extension Study Shows Sustained Benefits of Soliris® (Eculizumab) Treatment for Patients with Refractory Generalized Myasthenia Gravis
September 13, 2017
HTML PDF
Alexion Announces Restructuring to Advance Corporate Strategy
September 12, 2017
HTML PDF
Alexion to Host Call to Discuss Restructuring to Advance Corporate Strategy at 8:30 a.m. on September 12, 2017
September 11, 2017
HTML PDF
Alexion to Present at Upcoming Investor Conferences
September 5, 2017
HTML PDF
European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)
August 21, 2017
HTML PDF
Alexion Receives Three New U.S. Patents for Soliris® (eculizumab), Extending Patent Protection Into 2027
August 15, 2017
HTML PDF
Alexion and Sema4 Partner in Rare Disease Diagnostics and Systems Biology
August 10, 2017
HTML PDF
Alexion Reports Second Quarter 2017 Results
July 27, 2017
HTML PDF
Alexion to Report Second Quarter 2017 Results and Strategic Update on Thursday, July 27, 2017
July 11, 2017
HTML PDF